Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib versus bempedoic acid in high-risk dyslipidemia
NL-OMON61121Phase 3Not yet recruiting
- Sponsor
- Menarini Group
- Start
- Jul 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in dyslipidemia, Primary non-familial hypercholesterolemia and combined dyslipidaemia comparing Obicetrapib with Bempedoic acid (2 arms). Primary endpoint: Percentage change in LDL-C from baseline to Day 84. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
obicetrapibbempedoic acid
03
Conditions
dyslipidemiaPrimary non-familial hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on NL-OMON61121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61121.